A patient with a large, 12cm symptomatic desmoid tumor experienced significant spontaneous regression to 3cm while on active surveillance. This challenges the common assumption that only small tumors shrink on their own, highlighting the disease's unpredictability even in severe cases.

As more effective treatments for desmoid tumors become available, a critical unmet need is emerging: knowing when to stop therapy. Future research must focus on identifying signals, such as radiologic changes on MRI, to guide treatment duration. This will help clinicians avoid both the risk of early relapse from stopping too soon and the toxicity of unnecessary overtreatment.

Desmoid tumors exhibit highly variable behavior, acting as a chronic disease in some patients while being manageable in others. This necessitates a personalized, long-term treatment strategy rather than a standard protocol, often requiring a diverse armamentarium of therapeutic options to be used over a patient's lifetime as needs change.

The standard of care for desmoid tumors has shifted away from upfront surgery due to high recurrence rates and poor patient outcomes. Experts now recommend systemic or other local therapies first, reserving surgery only for emergencies or after careful multidisciplinary team review.

In patients with the genetic syndrome FAP, surgery for mesenteric desmoids is strongly contraindicated. The wound healing process itself is believed to initiate tumor growth, making surgery a potential cause, not a cure, unless for an anatomical emergency.

Surgical resection of desmoid tumors is now discouraged due to the risk of multifocal recurrence. A case demonstrated a patient developing multiple tumors throughout her leg 10 years after an initial surgery, illustrating how the tumor's finger-like growth can lead to widespread seeding if disturbed.

Clinicians should not underestimate the pain potential of desmoid tumors based on size. A case study showed a small 2.5cm tumor causing constant, debilitating pain that required nerve blocks for management, highlighting the poor correlation between tumor volume and symptom severity.

Treatment algorithms for desmoid tumors are highly dependent on tumor location. While medical therapy is preferred for mesenteric or head and neck tumors to avoid morbidity, surgery remains a viable first-line option for the specific case of abdominal wall tumors.

Because up to 20% of desmoid tumors regress on their own, the standard of care for patients with non-critical tumors is to "watch and wait" for 1-2 years. This approach avoids unnecessary treatment and allows physicians to observe the tumor's natural history.